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Oral cancer stem cells - properties
and consequences
???????????????????????????????????????????????????????????????????????
of medicine and pathology; however, some conceptual misunderstandings 
???????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????
is the misinterpretation of CSCs as a synonym of their normal counterparts, 
the well-known stem cells (SCs). Particularly in Dentistry, another common 
mistake is the misinterpretation of oral CSCs as normal tooth-derived SCs. 
The present review aims to clarify important concepts related to normal SCs 
and CSCs, as well as discuss the relevance of CSCs to the development, 
metastasis and therapy resistance of oral squamous cell carcinoma.
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Introduction
For several years the concept of “stem cells” has 
??????????????????????????????????????????????????????
important prospect of being able to create new human 
tissues in the laboratory and use them to replace those 
lost by injury or disease. Such stem cell concepts 
applied to Dentistry, as well as to general Medicine, 
could be greatly enhanced by researches exploring the 
ability of stem cells to generate new tissues such as 
mucosa and bone tissues and, eventually, regenerate 
dental tissues including perhaps even the whole teeth. 
Recently, however, the dental literature has begun to 
contain references to “cancer stem cells” (CSCs) and 
these have quite a different concept. These are the 
cells that have the ability to stimulate the growth of 
oral cancers and enable tumours to resist therapy. This 
review will describe how CSCs differ from normal stem 
cells, how they can be isolated and studied, how they 
have special properties and, of most importance, how 
they are responsible for the spreading of cancer and 
how they might be targeted for destruction. There is 
now good evidence that CSCs exist in most tumours 
but this review will focus mainly on oral squamous 
cell carcinoma, which comprises the great majority 
of malignant oral cancers.
Background of oral cancer
Oral squamous cell carcinoma (OSCC) is the 
most commonly occurring oral malignancy and one 
of the most widely occurring cancers throughout 
the world9,25,33. OSCC is a malignancy that arises in 
the squamous epithelium lining the oral cavity and 
includes tumours found on the tongue, lip, gingival, 
???????????????????? ???????????????? ?????13,25. The 
risk factors for development of OSCC include tobacco 
exposure, alcohol consumption, and infection with 
oncogenic viruses such as HPV9,35. The tumour can 
invade deeply into adjacent tissues of the tongue and 
???????????????? ????????? ?????????????????????? ??????
of the alveolar crest41.
Microscopically, OSCC usually shows variable 
degrees of keratinization, cellular and nuclear 
pleomorphism, and mitotic activity. They are graded 
as well-, moderately- or poorly-differentiated (grades 
1 to 3) according to WHO criteria23,43. The tumour’s 
features, including size and site, histologic malignant 
grade, perineural spread at the invasive front, 
lymphovascular invasion and tumour thickness, can 
???? ????????? ????? ???????? ??????????? ???? ??????????
for OSCC patients32; however, the main negative 
prognostic factor is the presence of lymph node 
metastasis, which occurs in 25 to 65% of cases15,29.
The treatment for early-stage OSCC is generally 
single modality, either surgery or radiotherapy. In 
cases of locally advanced OSCC, the treatment is 
multimodal, with either surgery followed by adjuvant 
radiation or chemo-radiation, as indicated by 
??????????? ??????????????????????? ???????????????27. 
Approximately half of all patients survive 5 years after 
??????????????????????? ??????????? ????????????? ????
stage of the disease at diagnosis35.
The various types of normal stem cells
The general term “stem cells” includes several 
????????????????????????????????????????????????????????
made is between (a) normal stem cells (SC), which 
are responsible for the development and maintenance 
of all of the tissues of the body, and (b) their diseased 
counterpart, called cancer stem cells (CSC), that have 
lost the close growth control that is a property of 
normal stem cells. The most primitive type of stem 
????????????????????????????????????????????????????????????
in development produce cells that retain the ability to 
generate all the different cell types of the adult body. 
They are therefore described as “totipotent” and, 
unusually for stem cells, they are transient. As the 
embryonic development proceeds, these totipotent 
stem cells become directed towards differentiation into 
the many distinct tissue types of the adult individual 
(e.g. stem cells for blood, bones, mucosa, etc.). As they 
do so they lose some of their developmental potential 
and become either “pluripotent”, that is, restricted to 
forming only a few types of tissues, or "unipotent", 
restricted to generating only a single tissue. Thus, 
several subtypes of stem cells exist in adult individuals, 
each with different potentialities depending on their 
developmental history. The epithelial stem cells of oral 
mucosal epithelia are typically unipotent and form only 
the type of epithelium typical of the region where they 
are found (Figure 1).
The general property that characterizes adult 
(somatic) stem cells is that they can be divided 
??????????????????????????????????????????????????????
a stem cell and one cell that differentiates itself into 
a functional tissue cell. This normal “asymmetrical” 
division pattern is important as it results in the 
maintenance of the same number of stem cells 
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while also providing another cell for tissue function. 
However, when it is necessary to replace stem cells, 
such as those lost after wounding, stem cells can be 
divided “symmetrically” to form two stem cells and 
thus increase their number.
Experimentally derived stem cells
Although normal adult stem cells can divide 
themselves to regenerate tissues throughout life, 
??????????????????????????????????????????????????????
laboratory. However, totipotent cells taken early in 
embryonic development have been shown to continue 
???????????????????????????????????????????????? ???????
losing their totipotent abilities. For this work, Martin 
Evans and colleagues were awarded the Nobel Prize 
in 2007, recognizing the great potential of such 
“embryonic stem cells” to allow new tissues to be 
regenerated in the laboratory. Further studies on 
the genes expressed by embryonic stem cells have 
?????????????????????????????????????????????????????
“stemness” and this led to another major step. It was 
??????????? ????????????????????????????????????????????
adult stem cells they regain the totipotent properties of 
embryonic stem cells. For his work with these “induced 
pluripotent stem cells (iPSCs), Shinya Yamanaka 
???????????????????????????????????????????????????
???? ? ??????????????? ??? ???? ?????? ??? ?????????????
Medicine and Tissue Bioengineering. However, this 
work also shows that although adult stem cells are 
normally restricted permanently to a particular tissue 
type, they can be manipulated experimentally to form 
different cell types (Figure 1). Such cell plasticity is 
also of interest to cancer development, progression 
and metastasis. Thus, stem cell research now has 
two different directions: (a) how to encourage the 
growth and differentiation of stem cells for tissue 
regeneration, and (b) how to prevent the growth of 
cancer stem cells to prevent the expansion, metastasis 
and recurrence of the tumours in which they are found.
Normal oral epithelium and oral cancer
??????? ???????????? ??? ???????? ??? ?? ??????????
squamous epithelium and although keratinocytes 
form the primary cell type of the tissue, these 
epithelia also contain a minority of cells such as 
melanocytes, Langerhans cells, Merkel cells, and 
?????????? ???????????? ??????? ????? ???????? ??? ????
?????? ????? ?? ??????????? ??? ????????? ???????? ??????
that is able to resist the forces of mastication, but 
other regions, where the epithelium acts as a lining 
Figure 1- Schematic view of normal stem cells (A) and cancer stem cells (B). A shows different sources of normal SCs, their biological 
???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
stem cells are totipotent, adult stem cells are unipotent but can regain totipotent properties under in vitro conditions, originating the induced 
pluripotent stem cells (iPSCs). In B, adult epithelial SCs can undergo malignant transformation after cumulative genetic alterations caused 
by carcinogens, generating CSCs. These CSCs retain the biological properties of the self-renewal and generation of differentiated (cancer) 
cells, leading to cancer development and further metastasis
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that is required to stretch, have a non-keratinied 
epithelium. Oral epithelia are formed of a number of 
cell strata known as the basal, spinous, granular and 
corneal layers in keratinized regions, and as basal, 
????????? ???????????????????????????? ??????? ???????
keratinized regions. In all regions, cell proliferation 
occurs in the basal cell layer to provide new cells 
that undergo differentiation as they move upwards 
through the strata and the whole epithelial component 
of the mucosa is renewed in 5-40 days depending on 
the region. The rapid tissue renewal that confers a 
remarkable regenerative potential to the oral mucosa 
is ultimately related to the presence and dynamics of 
the epithelial stem cells (eSC) present in the basal cell 
layer. The carefully ordered structure and balanced cell 
renewal found in normal oral mucosa is progressively 
lost with the development of cancer.
It was originally thought that all epithelial basal 
cells are similar and all divide themselves to produce 
cells that are committed to differentiation as a result 
of being randomly squeezed out of the basal layer 
by population pressure. However, measurements of 
regional differences in proliferation rates, and of the cell 
lineages produced by labelled cells, indicate that only 
a small fraction of the proliferating cells have the stem 
???????????????????????????????????????????????????????
that such stem cells form only a small fraction of the 
total dividing cells and that they divide quite slowly 
to produce cells committed to differentiation. These 
differentiating “transit-amplifying” (TA) cells have a 
high proliferative rate but a low self-renewal capacity, 
so they eventually differentiate into specialized cells 
that stop dividing and fully differentiate themselves11,12 
(Figure 2).
Such cell proliferation is fundamental for epithelial 
renewal but it requires tightly controlled mechanisms 
that balance epithelial cell production and loss. The 
loss of such balance can be resulted from the increased 
or decreased expression of genes (proto-oncogenes 
and their opposite, tumour suppressor genes) related 
to the control of the cell cycle and death. Accumulation 
of somatic mutations may alter the expression pattern 
of genes involved in the control of cell growth and 
differentiation leading to the loss of proliferative 
control that characterizes cancer. Such mutations arise 
as a result of long-term exposure to carcinogens such 
as tobacco and alcohol (Figures 1B and 2).
Oral cancer stem cells
As stem cells are ultimately responsible for all 
the normal tissue growth and renewal occurring in 
the body, it therefore logically follows that stem cells 
are also likely to be responsible for cancer growth. 
However, although the idea that CSCs stimulate the 
Figure 2- Schematic view of normal oral epithelium (A) and oral squamous cell carcinoma (B). In A, the asymmetric division of normal 
stem cells (SCs) found in the basal cell layer generates one daughter SC (self-renewal) and one daughter transit-amplifying cell committed 
to differentiation (small black box). In B, loss of balance of genes related to cell growth and death due to cumulative somatic mutations 
on SCs results on the development of cancer stem cells (CSCs), which retain the biological properties of self-renewal and generation of 
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
of tumours
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growth and spread of tumours has been discussed for 
many years, their existence has also been questioned. 
It might be thought that with the loss of proliferative 
control and spatial organization, the normal stem 
cell patterns would disappear. From what has been 
described above, it can be seen that if all dividing cells 
of a tumour have equal proliferative abilities they can 
all be considered stem cells and a sub-population of 
??????????? ?????????????????????????? ????????????????
????????????????????????????????????? ????????????????
cells and to test whether initiation and maintenance 
of tumours is restricted to the sub-population of the 
?????? ??????????? ???? ????? ?????? ?????? ????????? ????
the existence of such tumour-initiating stem cells was 
provided in 1997, when Bonnet & Dick found that only 
the small subpopulation of leukemic cells, marked 
by staining, positively for CD34 and negatively for 
CD38, was able to regenerate the original leukaemia 
when transplanted into immunodeficient mice5. 
???????????????????????????????????????????????????
by Al-Hajj and co-workers who reported in 2003 that 
only a subpopulation of breast cancer cells staining, 
positively for CD44 and negatively for CD24, could re-
initiate tumours with the cellular heterogeneity typical 
of the original tumour1. Since then, increasing evidence 
for the presence of such cells has been found for many 
tumours including those of the central nervous system, 
breast, prostate and pancreas22,31,39.
Many evidences that CSCs also play a central role 
in the pathogenesis and progression of carcinomas 
of the head and neck (HNSCC), including OSCC, 
have been found. Early tissue culture studies showed 
that only a subpopulation of OSCC cells can form 
expanding tumour colonies, suggesting that human 
OSCC may contain some form of stem cells24 and it was 
subsequently shown that only a small subpopulation 
of the cells in OSCC corresponds to tumour-initiating 
cells26,46?????????????????????????????????? ????????????
concept17,34 that the tumour mass is a mixture of (a) 
CSCs dividing themselves to feed the tumour’s growth, 
(b) transient amplifying cells that divide themselves 
a few times before maturing into (c) differentiated 
tumour cells that do not contribute to tumour growth4.
The isolation of CSCs from oral cancers has mainly 
been performed with the CD44 marker that was 
initially used to isolate breast cancer CSCs. CD44 is 
an adhesion molecule that binds itself to hyaluronan 
and its expression is necessary for the maintenance 
of the CSC’s properties. CSCs lose their “stemness” 
when CD44 is experimentally reduced44. However, 




Figure 3- Schematic view of the primary site of oral squamous cell carcinoma (A) and metastatic lymph node (B). In A, cancer stem cells 
???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
microenvironment, assuming a complete mesenchymal (CD44highESAlow/-ALDH-) or epithelial-mesenchymal (CD44highESAlow/+ALDH+) 
phenotype. This subpopulation of EMT-CSCs is able to invade the tumour’s stroma, migrate and reach blood and lymphatic circulation. 
Once they arrive at a metastatic lymph node (B), they revert back, through mesenchymal-epithelial transition (MET), to the proliferative 
non-EMT phenotype (CD44highESAhigh) to enable the formation of a metastatic tumour at that secondary site
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have therefore been sought. ALDH1 is an intracellular 
?????????????????????????????????????????????????????
via the oxidation of aldehydes, and ALDH-positive cells 
in HNSCC are reported to have typical CSC behavior 
and increased tumorigenic ability21. The combination 
of CD44 with other markers, such as ALDH1, may 
improve the specificity of CSCs’ recognition and 
isolation.
Cancer stem cells and treatment failure
As they are the cells stimulating tumour growth, 
elimination of CSCs is necessary for the elimination 
of tumours. However, many studies have now shown 
that CSCs are more resistant than other tumour cells 
to chemotherapy and radiotherapy7. In vitro assays 
show that when CD44-high CSCs are irradiated or 
exposed to chemotherapy, they may be over 10 times 
more resistant to apoptosis than CD44-low cells18. 
The sensitivity of surrounding normal tissues to high 
doses of chemo- and radio-therapies restricts the 
dose levels that can be administered and, despite the 
various methods of targeting, the dose provided may 
??????????????????????????????????????????????????????
the CSCs. Clinically, therefore, the tumour may appear 
to shrink, and even perhaps disappear, only for a few 
remaining CSCs to begin to divide and subsequently 
regenerate it. Local tumour recurrence is a major 
problem for OSCC therapy and elimination of CSCs is 
a target of therapy but one that is made more complex 
by the heterogeneity of CSCs as discussed below.
Epithelial to mesenchymal transition
The epithelial to mesenchymal transition (EMT) 
????????? ???????????????? ?????????????????????????
but it is also activated during wound healing and 
organ fibrosis40. Recent evidence indicates that 
genetic programs relevant for EMT are also activated 
in epithelial cancers and that the changes induced 
in cancer cells by EMT appears to play a central role 
in cancer progression and metastasis8,19. Epithelial 
?????? ????????????? ??????????????? ??? ?????????????
membrane and adjacent cells, but EMT allows them 
to acquire a mesenchymal cell phenotype that 
is migratory and invasive, and also has elevated 
resistance to apoptosis19,20. These changes are 
characterized by the down-regulation of E-cadherin, 
?????????????? ??? ?????????? ????? ???? ??????????????
to the nucleus, and up-regulation of mesenchymal 
molecular markers such as vimentin, fibronectin 
and N-cadherin28,36,42. There is also up-regulation of 
transcription factors such as SNAIL, TWIST, and LEF-1 
that promote EMT14,45.
Metastasis is a major therapeutic problem for 
OSCC and the presence of lymph node metastasis is a 
strong predictor of therapeutic failure. For metastasis 
of OSCC to occur, cells of the primary tumour need 
to undergo EMT, invade the surrounding tissue, gain 
access to lymphatic or blood vessels, and then survive 
transport to exit from vessels and invade a new tissue 
site38. Through the reverse process of mesenchymal-
to-epithelial transition (MET), the cells then transition 
back to the proliferative epithelial phenotype to form 
secondary tumours6. Applying this to the cancer stem 
cell concept suggests that CSCs can exist as two 
interchangeable populations and Biddle, et al.3 (2011) 
??????????????????????????????????????????????????
that uses EMT and MET to switch backwards and 
forwards between a proliferative epithelial phenotype 
(EPI-CSC; CD44highESAlow/+ALDH+) and a migratory 
mesenchymal phenotype (EMT-CSC; CD44highESAlow/-
ALDH-) (Figure 3). Of particular interest, EMT not 
only enables cell migration but also alters drug 
sensitivities so that EPI-CSCs and EMT CSCs respond 
quite differently to chemo- and radio-therapies2,3,16.
Future treatment perspectives
Surgical resection is still a major therapy for 
OSCC and is effective, especially in treating smaller 
lesions30. Current anti-cancer therapies for more 
advanced lesions are typically based on radio- and 
chemo-therapeutic agents that target proliferative 
cancer cells27. However, compared to the bulk of 
tumour cells, the resistance of EPI-CSC populations 
to such therapies is greatly enhanced due to their 
slow cell cycle and their mechanisms for rapid DNA 
repair and drug exclusion37. Consequently, although 
most non-CSC tumour cells may be eradicated with 
standard therapies, the therapy resistant CSCs may 
selectively survive the doses of radio- and chemo-
therapies that are achievable without major damages 
to the surrounding normal structures. With such 
partially effective therapies, CSCs can be expected to 
survive through a process similar to natural selection, 
and their self-renewal capacity can then enable them 
to regenerate themselves and stimulate the growth 
of a new tumour. To avoid such recurrence, therapy 
therefore needs to employ agents, or combinations 
of agents, which provide widely effective actions, 
along with better assays which may allow the 
Oral cancer stem cells - properties and consequences
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effective screening of new and existing drugs for 
their differential effects on all sub-types of CSCs and 
non-CSCs.
The molecular advances in tumour biology studies 
are guiding an individualized treatment approach. For 
example, a clinically validated chemo-predictive assay 
(ChemoID®) is now being tested for HNSCC, in which 
both CSCs and bulk tumour cells are challenged by 
various FDA-approved drugs and their combinations 
to determine the most effective chemotherapy 
scheme. This assay, although still not FDA-approved, 
was recently published as a new complementary 
procedure to HNSCC drug treatment, aiming at both 
the elimination of unnecessary toxicity in patients as 
well as avoiding ineffective chemotherapy regimens10.
A better understanding of CSC properties is crucial 
for the development of effective alternative strategies, 
for example, targeting stem cell maintenance, 
signalling pathways or blocking EMT/MET to prevent 
the switching of CSCs between drug resistant 
phenotypes.
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